Cftr Trikafta denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Trikafta as Non-Formulary — and What You Can Do

A non-formulary denial from UnitedHealthcare (UHC) means that Trikafta (elexacaftor/tezacaftor/ivacaftor) is not listed on the specific drug formulary tier covered under your benefit plan, or that it requires a formulary exception before the plan will pay. This is a coverage-design decision, not a clinical finding — and federal and state law provide clear pathways to challenge it.

## Why This Denial Happens

UHC negotiates formulary placement with manufacturers. When a specialty drug like Trikafta is placed on a non-covered or restricted tier, all claims for that drug are automatically denied at adjudication regardless of clinical appropriateness. The plan is required to have an exceptions process, but the patient or provider must actively invoke it.

## Your Federal Appeal Rights

• Formulary exception request: Before or concurrent with a formal appeal, submit a formulary exception request. UHC is required under ACA and CMS rules (for Medicare/ACA-market plans) and under most employer-plan procedures to grant exceptions when no covered formulary drug is medically appropriate for the patient.
• Internal appeal: Under ERISA §503 or applicable state law, a non-formulary denial is appeallable as a benefit determination. File within the deadline shown on the denial letter.
• External review (ACA §2719): If the internal process is exhausted without resolution, independent external review is available. Reviewers regularly override non-formulary denials when the patient cannot use a covered formulary alternative.
• Expedited review: Request the 72-hour expedited track when delay would seriously jeopardize health.
• Filing window: External review requests are generally due within approximately four months of the final internal denial — confirm the exact date on your notice.

## Documentation to Gather

1. Diagnosis and mutation confirmation — chart notes and genetic testing establishing CF diagnosis and the CFTR mutation type that brings this patient within Trikafta's FDA-approved indication. 2. Formulary alternative analysis — a prescriber letter explaining why every formulary-listed CFTR modulator is not medically appropriate for this patient (mutation-class mismatch, prior failure, contraindication per the prescribing label), citing the FDA label. 3. Medical-necessity letter — CF specialist attestation that Trikafta is medically necessary and that no covered formulary alternative is clinically equivalent for this patient. 4. Clinical severity documentation — lung function trends, exacerbation history, and nutritional data from the chart. 5. Cystic Fibrosis Foundation guideline reference — your prescriber can cite the applicable CFF care standard supporting Trikafta for this mutation class.

## Criteria-Mapping Structure

Obtain UHC's formulary exception criteria and its coverage policy for CFTR modulators. Then build a point-by-point table:

| Formulary Exception Criterion | Evidence Provided | |---|---| | No covered alternative is clinically appropriate | Prescriber analysis of each formulary alternative per FDA label | | Medical necessity of the specific drug | Mutation documentation + clinical severity data | | Guideline support | CFF care standard cited by prescriber |

A well-documented formulary exception request resolves many non-formulary cases at the pre-appeal stage, avoiding the need for external review entirely.